oncolytic virus cf33-expressing hnis/anti-pd-l1 antibody
Biologicalexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 18, 2021 (NCT05081492)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Oncolytic virusOTHER
Oncolytic virus other
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05346484 | Phase 1 | May 17, 2022 | Imugene Limited |
| NCT05081492 | Phase 1 | Oct 18, 2021 | City of Hope National Medical Center, Imugene Limited, National Cancer Institute (NCI) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Imugene Limited | For profit | 2 | 1 | 1 | 2021 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 1 | 1 | 2021 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1